• Olink and the COVID-19 pandemic

    Current number of planned/ongoing studies using Olink = 59

    As a provider of protein biomarker solutions for scientists seeking to re-shape future healthcare, Olink is taking the COVID-19 pandemic situation extremely seriously and is committed to support the crucial studies that will help better understand and eventually to better treat the disease.

    Actions speak louder than words

    Olink’s protein biomarker panels are already being used in a significant number of on-going and planned COVID-19 studies across North America, Europe and Asia, covering a range of objectives, including:

    Prediction & prognosis:

    • Understand basic biology and prognosis of disease severity
    • Patient stratification by disease severity
    • Longitudinal sampling (admission to recovery vs. death)
    • Prediction of cytokine release storms in COVID-19 patients
    • Prediction/prevention of ARDS (Acute Respiratory Distress Syndrome)
    • Outcome predictions in CVD patients with COVID19


    • Evaluation of re-purposed therapeutics
    • Patients undergoing plasma-exchange
    • Remdesivir
    • IFNbeta-1
    • IL-6
    • Bradykinin pathways (repurposed rare disease drug)
    • Chloroquine, Hydroxychloroquine,
    • Ruxolitinib
    • Camostat
    • Azithromycin
    • Lopinavir/Ritonavi.
    • Effect of p38 inhibition on COVID-19 patients and cytokine storm
    • Cardiac markers to determine use of ACE2 inhibitors
    • Re-purposed immunotherapy for allergies


    • Cancer
    • Cardiovascular disease
    • BMI
    • Renal dysfunction
    • Neurological effects
    • Hematological malignancies
    • Dermatological diseases
    • HIV

    We are offering significant discounts for customers who wish to analyze SARS-CoV-2 infected samples in our Analysis Service labs for  COVID-19 related studies:

    Contact us about discounted COVID-19 studies

    Olink has the most comprehensive solution available to help to rapidly identify the proteins and pathways involved in COVID-19 pathophysiology and to better understand the disease and its treatment.

    I am proud that we are taking our social responsibility during this pandemic by actively supporting the research community to carry out the critical research that is so desperately needed”.

    Ida Grundberg PhD, Chief Scientific Officer, Olink.

    Latest news on COVID-19 research using Olink

    As new information becomes available about specific ongoing COVID-19 studies using Olink panels, we will update our summary page (link below). Some current highlights include:

    • Proteins identifying new immune pathways & predicting the level of disease severity
      Researchers from the Radboud UMC in the Netherlands have published a preprint from a study where they used Olink to investigate inflammatory and other biomarkers of COVID-19 pathophysiology – link
    • ACE2 – protein of the moment 
      Two recent studies have looked at ACE2 expression in non-COVID-19 subjects, with findings that may throw more light on the signifcance of circulating levels of this membrane-bound receptor for SAR-CoV-2. – link
    • COVID-19 Technology Access Framework
      Through a collaboration with the Broad Institute, Olink has been acknowledged as a key technology in an intiative to ensure that COVID-19 research findings and data are shared rapidly and openly. We are proud that our platform will be used to help understand and overcome COVID-19 as quickly as possible – link
    • ACE-inhibitor treatment of hypertension for COVID-19 patients
      Olink has been used in an important study looking at the SAR-CoV-2 cellular receptor ACE2 . The authors also found genetic data to validate the Olink assay’s targeting of ACE2, which is important data for future studies – link

    READ MORE about all the latest news.

    Olink biomarker assays for COVID-19 research

    Our library of 1161 high-quality protein assays available as fourteen 92-plex panels is ideally suitable for targeted biomarker discovery, with a mix of well-established and exploratory proteins for a broad range of diseases and biological functions. Proteins of particular relevance for COVID-19 research (cytokines, chemokines and proteins with known links to viral infections and acute respiratory conditions etc) are listed in the Excel file below (short name, Uniprot ID and Olink panel(s) in which the assays are available).

    Download the Excel file

    Other information

    Please note that the requirement for pre-treatment of infected samples may vary according to the setup of individual labs. For example, ARCADIA at UMC in Utrecht, Netherlands are currently accepting non-treated samples from patients with SARS-CoV-2 infections. If you have any questions around sample pre-treatment for Olink studies, please contact us.

    • Olink is taking every precaution for the well-being of its employees and to ensure that our production and Analysis Service departments are working effectively to continue to support the research community and its vital work – link

    Can we help you?

    If you have any questions or comments, please contact us using the form below.

    Visit us on LinkedIn